SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus supplement, the accompanying prospectus and the documents incorporated by reference therein and herein contain forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this prospectus supplement, the accompanying prospectus, and documents incorporated by reference herein and therein other than
statements of historical fact, including statements regarding our future results of operations and financial position, and statements including, but not the success, cost, and timing of our product candidate development activities and ongoing and
planned clinical trials, our plans to develop and commercialize antibodies, including our two checkpoint agonists in clinical-stage development: rosnilimab and ANB032, our ability to develop our market candidates, the likelihood that the clinical
data generated in any study we performed, are performing, or plan to perform in a non-U.S. jurisdiction will be subsequently accepted by the U.S. Food and Drug Administration and/or by foreign
regulatory authorities outside of the jurisdiction where the study was being performed, the potential benefits and advantages of our product candidates and approaches versus those of our competitors, the success of competing therapies that are or
may become available, the timing of and the ability to obtain and maintain regulatory approvals for our product candidates, partnered product candidates and/or product candidates for which we may receive royalties, the rate and degree of market
acceptance and clinical utility of any approved product candidates, the size and growth potential of the markets for any approved product candidates, and our ability to serve those markets, our commercialization, marketing, and manufacturing
capabilities and strategy, our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, regulatory developments in the U.S. and foreign countries, the impact of political, economic or
public health events on our business and the United States and global economies, our ability to attract and retain key scientific or management personnel, general macro-economic factors, including volatility in equity markets, and fluctuations in
interest rates and foreign exchange rates, our ability to obtain funding for our operations on favorable terms or at all, including funding necessary to complete further development and commercialization of our product candidates, our ability to
find a licensing partner for imsidolimab and etokimab, the timing and ability of our collaborators to develop and commercialize our partnered product candidates, our use of the net proceeds from this offering and other financing transactions and our
estimates regarding expenses, future revenue, capital requirements, and needs for additional financing, are forward-looking statements. The words believe, may, will, potentially, estimate,
continue, anticipate, predict, target, intend, could, would, should, project, plan, expect, and similar expressions
that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part II, Item 1A,
Risk Factors in in our Annual Report on Form 10-K for the year ended December 31, 2023 and in our Quarterly Reports on Form 10-Q for the quarters ended
March 31, 2024 and June 30, 2024, as well as those discussed in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and accompanying prospectus and any free
writing prospectus. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our
business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the
forward-looking events and circumstances discussed in this prospectus supplement, the accompanying prospectus, and documents incorporated by reference herein and therein may not occur and actual results could differ materially and adversely from
those anticipated or implied in the forward-looking statements.
S-5